Ashton Thomas Securities LLC Reduces Position in Boston Scientific Corporation $BSX

Ashton Thomas Securities LLC trimmed its stake in Boston Scientific Corporation (NYSE:BSX) by 1.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,499 shares of the medical equipment provider’s stock after selling 165 shares during the period. Ashton Thomas Securities LLC’s holdings in Boston Scientific were worth $1,128,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. 1248 Management LLC purchased a new position in shares of Boston Scientific during the 1st quarter valued at about $26,000. Y.D. More Investments Ltd purchased a new position in Boston Scientific during the first quarter valued at approximately $27,000. Sound Income Strategies LLC boosted its position in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares during the period. Oliver Lagore Vanvalin Investment Group purchased a new stake in shares of Boston Scientific in the second quarter worth $37,000. Finally, Activest Wealth Management raised its position in shares of Boston Scientific by 6,216.7% during the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 373 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares of the company’s stock, valued at $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock valued at $17,972,457 in the last three months. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Boston Scientific stock opened at $96.36 on Friday. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm’s fifty day moving average is $103.10 and its 200 day moving average is $102.06. The company has a market cap of $142.78 billion, a price-to-earnings ratio of 57.36, a PEG ratio of 2.31 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm’s revenue was up 22.8% on a year-over-year basis. During the same quarter last year, the business posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on BSX. Wells Fargo & Company increased their price target on Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. Raymond James Financial increased their target price on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 24th. BTIG Research boosted their price target on Boston Scientific from $127.00 to $132.00 and gave the stock a “buy” rating in a report on Wednesday. Jefferies Financial Group reaffirmed a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Finally, Leerink Partners boosted their target price on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday. Three analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Boston Scientific presently has a consensus rating of “Buy” and an average target price of $120.79.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.